A study on antigenicity of recombinant human interferon alpha A (LBD-007) in mice and guinea pigs.

Antigenicity of recombinant human interferon alpha A (LBD-007), a newly developed drug for myeloid leukemia and hepatitis, was investigated in mice and guinea pigs. The following results were obtained: 1. Mice showed no production of antibodies against LBD-007 inoculated with aluminum hydroxide gel (alum) as an adjuvant, judged by the heterologous anaphylaxis (PCA) test using rats. On the other hand, antibodies against ovalbumin (OVA) inoculated with alum were definitely detected. 2. In the studies with guinea pigs, both the inoculation of LBD-007 only and of LBD-007 with complete Freund's adjuvant (CFA) as an adjuvant did not produce positive reactions in any of homologous active systemic anaphylaxis (ASA). On the other hand, the inoculation of ovalbumin with complete Freund's adjuvant (CFA) produced positive reaction in both of PCA and ASA. 3. These findings suggested that LBD-007 has no antigenic potential in mice or guinea pigs.